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Highlights 
  The lipoxygenases 12R-LOX and eLOX3 act in tandem in epidermal barrier function  They oxidize linoleic acid esterified in -hydroxyacyl ceramide to hepoxilin  This acts as a signal for hydrolysis of the oxidized linoleate from the ceramide  The free ceramide -hydroxyl is bonded to protein forming a key barrier component  Understanding the role of hepoxilins can lead to therapy of skin diseases. 
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Summary 
 
 
This review covers the background to discovery of the two key lipoxygenases (LOX) involved in 
epidermal barrier function, 12R-LOX and eLOX3, and our current views on their functioning. In 
the outer epidermis, their consecutive actions oxidize linoleic acid esterified in -hydroxy-
ceramide to a hepoxilin-related derivative. The relevant background to hepoxilin and trioxilin 
biochemistry is briefly reviewed. We outline the evidence that linoleate in the ceramide is the 
natural substrate of the two LOX enzymes and our proposal for its importance in construction of 
the epidermal water barrier. Our hypothesis is that the oxidation promotes hydrolysis of the 
oxidized linoleate moiety from the ceramide. The resulting free ω-hydroxyl of the -
hydroxyceramide is covalently bound to proteins on the surface of the corneocytes to form the 
corneocyte lipid envelope, a key barrier component. Understanding the role of the LOX enzymes 
and their hepoxilin products should provide rational approaches to ameliorative therapy for a 
number of the congenital ichthyoses involving compromised barrier function. 
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The mammalian epidermal water barrier: a short primer 
One of the most important functions of the skin is the maintenance of a barrier to water 
vapor diffusion to the environment [1-3]. Substantial evidence demonstrates that the main 
determinant of the permeability properties of the skin is the lipid composition and organization in 
the outer layers of the epidermis, the stratum corneum [4, 5]. The mammalian stratum corneum 
(SC) consists of flat, dead cells, called corneocytes, surrounded by a protein layer, the cornified 
envelope (CE), in turn surrounded by a monolayer of lipids, the corneocyte lipid envelope 
(CLE), covalently attached to the CE. The spaces between corneocytes are filled with a matrix of 
intercellular lipids, mainly cholesterol, free fatty acids, and ceramides, which altogether organize 
in layers called lamellae in mammals. The backbones of the lamellae are the ceramides, 
molecules formed by a sphingoid base amide-linked to a fatty acid of varying chain length [6-
12]. The intercellular lamellae are thought to impede excessive evaporation through the skin, as 
their disruption leads to increases in transepidermal water loss (TEWL) [13, 14]. Fundamental to 
the formation of a fully competent barrier is the need of linoleic acid, incorporated in a particular 
class of ceramides unique to the epidermis (EOS, esterified omega-hydroxyacyl-sphingosine) [5, 
15, 16]. The activity of epidermal lipoxygenases (LOX) is crucial to understand the 
physiological process that links the need of essential fatty acids to ensure the normal formation 
and maintenance of the permeability barrier of the skin. Figure 1 illustrates the main structural 
components of the barrier relevant to the role of LOX enzymes. 
 
Barrier genes and ichthyosis 
Genetic anomalies in the complex physiological process of epidermal barrier formation result in 
scaly skin diseases (ichthyoses) with medical complications like dehydration, infections, chronic 
blistering, and rapid-calorie loss [17-20]. Gene mutations implicated in the autosomal recessive 
congenital ichthyoses (ARCI) include ALOX12B, ALOX3, CYP4F22, ichthyin and TGM-1 [18, 
21-24]. Cytochrome P450 CYP4F22 may be responsible for synthesis of the -hydroxyl of -
hydroxy-acyl ceramides. ichthyin is a predicted transmembrane protein with undetermined 
function. TGM-1 cross-links the proteins forming the corneocyte envelope (CE), and is also 
implicated through in vitro studies and a knock-in mouse mutation in catalyzing the covalent 
bond between -hydroxy-acyl ceramides and the CE, forming the CLE [25, 26], (albeit with 
human studies showing that lamellar ichthyoses due to mutations in this isozyme have a normal 
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CLE) [27]. The fact that inactivating mutations in all of these genes produce related skin 
phenotypes supports the idea that they are elements of the same physiological process. 
 
The genetic evidence establishes that the integrity of the mammalian epidermal water barrier 
requires the normal functioning of 12R-lipoxygenase (12R-LOX, human gene ALOX12B) and 
epidermal lipoxygenase-3 (eLOX3, gene ALOXE3) [18, 21, 28-30]. LOX enzymes are 
dioxygenases that oxygenate lipids (polyunsaturated fatty acids and their esters), yet their 
specific role in skin barrier function is not well understood. In general terms, and taking parallels 
from better known LOX enzymes, their functions may be to produce oxidized lipids as signaling 
molecules, to induce structural changes through an enzyme-catalyzed lipid peroxidation, or 
rarely, to help initiate the mobilization of lipids (reviewed in ref. [31]). Our current model 
suggests a function mainly related to the second of these possibilities, the induction of structural 
changes. 
 
The present paper stands as an update and major revision of an earlier review [32]. Before going 
into specifics on our current model of the workings of 12R-LOX and eLOX3 in epidermal barrier 
function, we present overviews of the background history of the two LOX enzymes and of their 
essential fatty acid substrate in the skin. 
 
Historical perspective on 12R-Lipoxygenase 
Mammalian 12R-LOX and eLOX3 remained undetected until the late 1990’s. The existence of 
LOX enzymes in the plant kingdom was recognized over 70 years ago [33], and the more modest 
levels of LOX enzyme activities in animal tissues were first identified in the mid-1970s. That 
work established the existence of a 12S-LOX in blood platelets [34, 35], a 5S-LOX in leukocytes 
(catalyzing the first steps in leukotriene biosynthesis) [36], and a 15S-LOX in reticulocytes [37]. 
Closer examination over the years revealed the expression of these enzymes in many other 
mammalian tissues [38]. 
 
The “S” in 12S-, 5S- and 15S-LOX enzymes refers to the mirror image form of the fatty acid 
hydroperoxide product. “R” chirality LOX enzymes were unknown. Then in the mid-1980s 
enzyme activities in invertebrate animals (corals, starfish, sea urchins) were characterized that 
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synthesized “R” chirality fatty acid hydroperoxides [39]. In the mid-1990s, purification of one of 
these invertebrate R-LOX proteins and its molecular cloning revealed a close sequence 
homology to the plant and animal S-LOX enzymes [40]. Differences in substrate binding were 
proposed that could explain how structurally related enzymes can form products of one mirror 
image form or the other [40, 41]. 
 
The first indication of a role for oxidized polyunsaturated fatty acids in skin biology came in the 
mid 1970’s when an accumulation of 12-HETE (12-hydroxyeicosatetraenoic acid, i.e. 12-
hydroxy-arachidonic acid) and free arachidonic acid was discovered in the involved epidermis of 
psoriasis [42]. At the time, it was presumed that the 12-HETE arose from the activity of 12S-
LOX (subsequently identified in the germinal layer cells of the mammalian epidermis [43]). A 
decade later the psoriatic product was shown to be mainly 12R-HETE [44]. It took another 
decade of research before the “culprit” enzyme in this case was identified as the uncommon type 
of R-lipoxygenase, 12R-LOX, the only R-LOX in mammalian tissues [45, 46]. 
 
Historically the enzymatic oxidation of arachidonic acid in mammalian biology shows a strong 
association with the biosynthesis of pro-inflammatory lipid mediators [47], and this remains a 
focus of eicosanoids in skin inflammation and immunity [48]. Synthesis of the prostaglandin 
products of the cyclooxygenase pathway is inhibited by NSAIDs, and the leukotriene products of 
5-LOX have their pro-inflammatory actions blocked by receptor antagonists such as Singulair® 
and Accolate® [47]. Initially therefore, it was natural to equate the synthesis of 12R-HETE in 
psoriasis with the inflammation in the epidermis. Yet 12R-HETE itself showed only modest pro-
inflammatory activity [49]. From a current perspective, the abundance of 12R-HETE in psoriasis 
may reflect merely the co-occurrence of free arachidonic acid (not present normally, but a facet 
of the inflammation in psoriasis) with an over-abundance of the granular cells of the upper 
epidermis, the natural site of 12R-LOX expression in healthy skin. Having the arachidonic acid 
available as substrate together with high expression of 12R-LOX may account for the excess of 
12R-HETE in psoriatic epidermis. In fact in normal epidermis, there is only one definitive 
account of the synthesis of 12R-HETE, barely detectable as a product of [14C]arachidonic acid 
metabolism in human hair roots [50].  
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In primary cultures of human keratinocytes there is no detectable 12R-LOX activity (they 
produce only traces of 15-HETE [51, 52]). The absence of 12R-LOX is likely attributable to its 
association with the late stages of keratinocyte differentiation, a condition that requires special 
long-term treatments to mimic in culture [53], and not studied so far with regard to LOX enzyme 
activities. (A prominent 12-LOX activity was detected in normal human epidermis, but the R/S 
chirality of the 12-HETE was not determined [54]). Despite the hard to detect activity, 
immunohistochemical evidence clearly defines the occurrence of 12R-LOX (and eLOX3) in the 
outermost cells of the stratum granulosum in normal mammalian epidermis [29, 30]. We also 
have evidence from in situ analysis in human skin that 12R-LOX mRNA expression occurs in 
the outermost epidermal cells that retain a nucleus (Figure 2). Although 12R-LOX expression is 
not entirely skin-specific, no symptomology or phenotype is reported in relation to the limited 
expression in other tissues. While mRNA transcripts for 12R-LOX are detectable by RT-PCR in 
several other tissues (and similarly for eLOX3) [55, 56], the only instance confirmed so far with 
catalytically active enzyme is a weak activity of 12R-LOX in human tonsils [57]. 
 
The role of 12R-LOX in healthy skin is quite different from the earlier implications of its 
appearance in psoriasis, and we now know that the natural substrate of 12R-LOX is a linoleate 
ester rather than arachidonic acid. As firmly established from analysis of the gene inactivation in 
humans and mice, the biological role of 12R-LOX is helping to seal the permeability barrier of 
the outer epidermis, an activity that entails intimate cooperation with eLOX3 in synthesis of 
linoleate-derived “hepoxilins”. 
 
“Hepoxilins” 
Fatty acid hydroperoxides are easily broken down through non-enzymatic transformations, 
including into fatty acids in which the original two oxygen atoms of the hydroperoxide moiety 
are rearranged in the molecule to form one epoxide and one hydroxyl group [58]. Non-
enzymatically, these epoxy-hydroxy (also called epoxyalcohol) derivatives are produced as a 
mixture of isomers.  
 
The name “hepoxilin” was coined in the mid-1980s to describe epoxyalcohol products of the 
12S-LOX-derived arachidonic acid hydroperoxide, 12S-HPETE [59]. They were considered to 
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be derived enzymatically, although at the time there was scant evidence to support the 
contention. “Hepox” stood for hydroxy-epoxy and “ilin” came from an activity as an insulin 
secretagogue (albeit an activity not confirmed to be of physiological significance). All fatty acid 
hydroperoxides readily give rise to epoxyalcohol derivatives, although strictly only derivatives of 
the arachidonic acid hydroperoxide 12S-HPETE merit the connotation “hepoxilin”. Nonetheless, 
all the others can be considered as hepoxilin-related or hepoxilin-type fatty acid derivatives [32]. 
For example, the term is commonly applied to the epoxyalcohols formed by eLOX3 from 
linoleate hydroperoxides. 
 
Hepoxilins are classified as A-type or B-type [60]. When a fatty acid hydroperoxide rearranges 
into epoxyalcohols, the new OH group can be separated from the new epoxy group by a double 
bond (hepoxilin A, HxA, chemically an “allylic” epoxide, readily hydrolyzed in mild acid e.g. 
pH 3), or the OH can be next to the epoxide (hepoxilin B, HxB, more stable to mild hydrolysis 
conditions) (Figure 3). Non-enzymatic synthesis produces a mixture of HxA- and HxB-type 
epoxyalcohols, and each of these is a mixture of R- and S-hydroxy isomers. So, non-
enzymatically, four major hepoxilin products are formed from 12S-HPETE. Because of the 
differences in chemical stability, the HxB-type is the more commonly detected in tissue extracts, 
whereas the HxA-type may appear as the corresponding hydrolysis products, the trioxilins 
(Figure 3). The detection of hepoxilin and trioxilin derivatives in human epidermis occurred 
along these lines. 
 
Analysis of the hepoxilin/trioxilins in human and murine epidermis suggests that the majority of 
the free products are “true” hepoxilins originating from 12S-HPETE. Freshly isolated human 
epidermal cells catalyze the stereoselective biosynthesis of HxB3 from arachidonic acid and 12S-
HPETE [54, 61], and the levels are greatly increased in the lesion epidermis in psoriasis, along 
with the corresponding trioxilins [62]. The recent studies in Aloxe3 knockout mice indicate that 
free hepoxilins are measureable in the normal murine epidermis (along with purely 12S-HETE) 
and that the synthesis is eLOX3-dependent [30].  
 
Aside from hydrolysis promoted by the acidic conditions used for fatty acid extraction, formation 
of trioxilins in cells is likely to be catalyzed by epoxide hydrolases (EH). In 1989 a specific 
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hepoxilin EH was isolated from rat liver with an observed preference for hepoxilin A3 over 
leukotriene A4 [63]. However, it was shown recently that this activity is indistinguishable from 
mammalian soluble epoxide hydrolase (sEH) [64]. Because moderate expression of sEH has 
been shown in human epidermis, the presence of trioxilins both from AA and LA is possible, 
warranting further investigation [65]. The substrate specificity with regard to possible EOS 
trioxilin moieties should also be examined. Novel candidate EH genes were described recently 
and the first of these enzymes to be characterized (termed EH3) is highly active in the hydrolysis 
of fatty acid epoxides [66]. “Skin” is among the tissues showing strong expression of EH3 [66], 
and clearly it is of interest to define the location of its expression more precisely. 
 
 
A historical perspective on eLOX3 
eLOX3 was cloned from mouse epidermis cDNA in the late 1990s by Fürstenberger, Krieg and 
colleagues as one of three newly discovered LOX genes [67, 68]. Two of the expressed proteins 
were characterized as the mouse 8S-LOX and 12R-LOX. No catalytic activity could be found 
with the third, so it could only be named as epidermal lipoxygenase-3 (eLOX3, human gene 
ALOXE3) [69]. 
 
The paradigm-shifting report that mutations in the human 12R-LOX or eLOX3 genes are 
associated with congenital ichthyosis included the insightful suggestion that because a mutation 
in either of the two LOX genes produces a similar phenotype, the two LOX enzymes may 
function in the same metabolic pathway [21]. This prompted further investigation of the 
biochemical activities of eLOX3, with the finding that the enzyme exhibits hydroperoxide 
isomerase activity, converting fatty acid hydroperoxides to specific hepoxilin-type derivatives 
(and also to fatty acid ketones) [70]. In contrast to the non-enzymatic hepoxilin synthesis 
discussed in the previous section, the hepoxilin products of eLOX3 are specific epoxyalcohol 
isomers, with just one chiral form of the new hydroxy group. For example, eLOX3 converts 12R-
HPETE specifically to an 8R-hydroxy-11R,12R-epoxide, a single HxA-type epoxyalcohol [70]. 
Mechanistic studies on eLOX3 suggest that its unusual hydroperoxide isomerase activity is 
related to a lack of access of molecular oxygen within the active site, which allows redox cycling 
of the catalytic iron and efficient metabolism of fatty acid hydroperoxides [71, 72]. 
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We hypothesize that it is linoleate esterified in epidermal-specific ceramides that are the natural 
substrates for 12R-LOX and eLOX3 and that these activities underlie the role of the LOX genes 
in skin barrier function. Actually, the linoleate hydroperoxides 9-HPODE and 13-HPODE are 
not outstandingly good substrates of eLOX3, at least not as the free fatty acids [73]. But this is 
not directly relevant according to our current hypothesis on the natural physiological substrates 
of 12R-LOX and eLOX3.  
 
The crucial requirement for one essential fatty acid, linoleate 
When the hydroperoxide isomerase activity of eLOX3 was first discovered it was shown that 
12R-HPETE is a particularly good substrate [70]. If 12R-LOX and eLOX cooperate in their 
activities to produce a hepoxilin-type product, it appeared to make sense that the primary 12R-
LOX product from arachidonic acid (12R-HPETE) should be the substrate for eLOX3. But in 
retrospect this was discounting a long line of evidence from studies of essential fatty acids and 
their role in the epidermis. The fact is that arachidonic acid is almost absent from the outermost 
cells of the mammalian epidermis. There is excellent biochemical evidence from fatty acid 
analyses and from feeding studies in animals that the physiologically relevant essential fatty acid 
in relation to mammalian epidermal barrier function is solely linoleic acid [74]. 
 
The need for an essential fatty acid in barrier function was first recognized through the classic 
work of George and Mildred Burr, who discovered the dietary requirement for an “essential fatty 
acid” (EFA). They showed that one of the obvious symptoms of a dietary deficiency is increased 
TEWL and the development of a scaly skin phenotype [75, 76]. Topical application of EFA 
alleviates the skin symptoms [77]. Later it was shown that although feeding arachidonic acid 
cures the symptoms, the mechanism involves its retroconversion to linoleate [78]. The scaly skin 
also develops in EFA deficiency in humans and is reversible by adding linoleate back to the diet 
[79]. 
  
A key observation, highly relevant to the involvement of LOX enzymes, is that EFA deficiency 
is associated with a loss of linoleate (C18:26) in the epidermis and its replacement with oleate 
(C18:19). Oleate has only one double bond and is not a LOX substrate. Thus, either 
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inactivating mutations in one of the key LOX enzymes or a deficiency in the epidermal LOX 
substrate (linoleate) results in loss of integrity of the epidermal water barrier. 
 
EFA and ceramides, intimately linked in the epidermis 
Linoleate is by far the most abundant EFA in the epidermis, wherein it is mainly esterified to the 
omega hydroxyl of the amide-linked very long-chain fatty acid (VLFA, C28-C36) in a class of 
ceramide specific to the epidermis, esterified omega-hydroxyacyl-sphingosine (EOS) [16]. EOS 
is an important structural ceramide in the intercellular lamellae. In addition, a portion is further 
converted to omega-hydroxyacyl-sphingosine (OS) and omega-hydroxy-VLFA that are 
covalently attached to the external face of the cornified cell envelope (CE) composed of cross-
linked proteins (Figure 4) [25, 80]. These covalently bound lipids form the corneocyte lipid 
envelope (CLE) [81]. 
 
Proposed role of linoleate and LOX enzymes in construction of the epidermal barrier 
Figure 5 presents our proposal on the involvement of the two LOX enzymes in construction of 
the epidermal water barrier. The eponymous organelles of the stratum granulosum, the lamellar 
granules (or lamellar bodies), contain lipid precursors and a battery of hydrolytic enzymes [82, 
83]. As illustrated at step 1 in Figure 5, glucosyl-EOS is a constituent of the limiting membrane 
of the lamellar bodies, with its glucose moiety on the inside [84, 85]. At stage 2, as the granules 
fuse with the plasma membrane, the molecules of glucosyl-EOS expose the glucose moieties on 
the outside, the very long chain fatty acid of EOS spans the bilayer, and in this rendering the 
molecule is folded in a U-shape with the linoleate chain in the membrane. As differentiation 
proceeds, the glucosyl-EOS is deglycosylated and the two LOX enzymes oxidize the linoleate 
tail (Figure 5, step 3), producing an “oxygen signal” as the more polar carbon chain no longer 
strongly favors the lipid environment. We hypothesize that the oxidized linoleate will serve as 
substrate for an esterase/hydrolase, which cleaves the oxidized linoleate to form OS with a free -hydroxyl (Figure 5, step 4). This lipase (not identified to date) could be released from the 
lamellar bodies and activated in the intercellular spaces of the SC (see ref [86]), or be 
intracellular, as currently assumed for the two LOX enzymes. Finally the ceramide OS will be 
covalently coupled to the polymerized protein of the CE via the action of transglutaminase, thus 
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forming the corneocyte lipid envelope (CLE) of the completed epidermal barrier (Figure 5, step 
5). 
 
Evidence supporting the role of the LOX enzymes in barrier function 
The skin phenotype in gene inactivation and knockout studies highlights the essential role of 
12R-LOX and eLOX3 in barrier formation and prevention of transepidermal water loss, and the 
specific location of the LOX enzyme expression in the outer epidermis is consistent with this 
role. Furthermore, biochemical analyses show that linoleate (C18:26, a LOX substrate) is the 
sole EFA required for skin barrier integrity and that its replacement by oleate (C18:19, not a 
LOX substrate) in EFA deficiency results in barrier defects. Our working hypothesis of the 
involvement of the two LOX enzymes in the oxidation of linoleate-containing ceramides and 
formation of the CLE is supported by the following observations [87]: 
i)  Normal pig and murine epidermis contain low levels of oxidized species of linoleate in the 
EOS ceramides. 
ii)  These oxidized species of linoleate in the ceramides are chiral, with the hallmark of 12R-
LOX and eLOX3 activity. The oxidized species are predominantly 9R-HODE, 9-keto-
linoleate, and hepoxilin-related 9R,10R-epoxy-13R-hydroxy and/or 9R,10R-epoxy-13-
oxo-linoleates. 
iii)  These oxidized ceramides are almost absent in the epidermis of 12R-LOX knockout mice. 
iv)  The epidermis of 12R-LOX knockout mice contains ~2-fold higher amounts of unoxidized 
EOS, indicating accumulation of the LOX substrate. 
v) Covalently bound ceramides in the epidermis of 12R-LOX knockout mice are severely 
reduced to only a few percent of the wild-type level, and in line with this, the CLE is 
largely absent in the epidermis of 12R-LOX knockout mice. 
vii) eLOX3 knockout animals show a slightly less severe phenotype than the 12R-LOX 
knockouts (albeit neonatal lethal due to TEWL by ~10 hours), and this is associated with 
a reduction in covalently bound ceramides to about half of the normal levels [30]. 
 
Speculations on additional roles of oxidized linoleate 
Structural versus signaling roles - Although ceramides EOS with oxygenated linoleate are 
present in the epidermis of pig and mouse [87], and probably in humans as well, it appears that 
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the quantities present are insufficient to support a direct structural role. Indeed, if the hepoxilin 
(or trioxilin) tails serve as a signal for esterases and are hydrolyzed to form ceramides OS as we 
propose, then the majority of the 12R-LOX/eLOX3-derived hepoxilins should be present in the 
SC in their free form. The linoleate-related hepoxilins released in this manner might exert a 
signaling function in several processes related to components of the permeability barrier of the 
skin. This is also the case for the arachidonate-derived hepoxilins [30, 61, 62]. For example, it 
has been hypothesized that hepoxilins might be ligands for the plasma membrane receptor 
“ichthyin” [88]. Although the functions of ichthyin are not clear to date, ichthyin seems to 
interact with a fatty acid transporter of the endoplasmic reticulum, FATP4, which incorporates 
exogenous fatty acids into the cells [22, 89]. Patients with mutations in ALOX12B, the gene that 
codes for 12R-LOX, show a decrease in the expression of FATP4 but in an up-regulation of 
ichthyin [22]. Mutations in FATP4 itself are associated with ichthyosis prematurity syndrome 
[90, 91]. 
 
Potential interactions with epidermal PPARs - Hepoxilin-type products released from the 
ceramides have also been hypothesized to be activators of peroxisome proliferator activated 
receptors (PPARs). Although 12R-HPETE-derived (arachidonate) hepoxilins and trioxilins are 
activators of PPAR [92], this has not been tested using the linoleate-derived hepoxilins. PPARs 
in the skin are associated with various functions, including differentiation, proliferation, immune 
response, wound healing and lipid metabolism [93]. In relation to barrier function, Hanley and 
Feingold established an interesting role for PPARα as a transcriptional regulator of 
transglutaminase [94]. Quite possibly the LOX metabolism of linoleate may serve a dual purpose 
within skin: firstly, allowing cleavage of the linoleate moiety from the long chain ceramides, and 
secondly, by up-regulation of transglutaminase (responsible for ceramide coupling to corneocyte 
proteins), thus forming an efficient self-regulating system and reinforcing the crucial role of 
LOX within the skin via a novel-signaling pathway. 
 
Barrier restoration - After disruption or following a change in environmental conditions that 
requires adjustment of TEWL, the permeability barrier needs to be built at a high rate. In this 
scenario, lamellar bodies will extrude their contents at a higher rate, and free hepoxilin 
concentration might be higher, which might promote the formation of lamellar bodies through 
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the activation of fatty acid transporters, such as FATP4, via interaction with ichthyin. Activation 
of PPARs will also increase cell proliferation and differentiation (Figure 6). Altogether, these 
mechanisms will result in a prompt response of the permeability barrier of the skin to diverse 
environmental conditions. 
 
Future directions 
Identification and characterization of the putative lipase - According to our working hypothesis 
on LOX enzymes and barrier function, 12R-LOX and eLOX3 oxidize the linoleate in EOS 
ceramide, allowing an esterase or hydrolase to recognize and cleave the oxidized linoleate ester, 
thus providing OS for synthesis of the CLE. The key lipase/esterase/ hydrolase enzyme that uses 
oxidized-EOS as substrate remains to be identified. Although it is well precedented that lipases 
will preferentially cleave a variety of oxidized lipids from cell membranes [95-97], the 
specificity implied in our working model is remarkable. The putative esterase/hydrolase has to 
recognize and cleave oxidized linoleate of a particular chirality and chemical structure, resulting 
from the coordinated action of both 12R-LOX and eLOX3 on ceramides EOS. There is no 
evidence so far for an esterase that will recognize and cleave a particular oxidized species, as 
opposed to merely peroxidized lipid, yet that is what might be inferred in this case. 
 
Characterization of 12R-LOX/eLOX3 products in human epidermis -  The enzymatic activity of 
12R-LOX is relatively low in the conditions of the SC, and because the oxygenated hepoxilin-
EOS ceramides are present in small concentrations in the epidermis, their detection and 
identification has posed a challenge. Epoxyalcohols, hydroxides and ketones of ceramides EOS 
have been detected in the epidermis of pig and mouse using HPLC coupled with UV and MS 
detection [87]. The presence of these molecules in human epidermis has not been firmly 
established yet. The qualitative and quantitative characterization of hepoxilin-EOS ceramides in 
normal and diseased human skin will have clinical implications in the search for a rational basis 
for treatment of several pathologies. If hepoxilin-EOS ceramides perform a structural function, 
they should be distributed throughout the entire depth of the SC. If they act exclusively as signals 
for esterase activity, they would be intermediates of a complex enzymatic chain reaction. In this 
case, only small amounts would remain in the lower layers of the SC, where 12R-LOX and 
eLOX3 are located. 
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Implications for therapeutics – Based on our model of the actions of the LOX enzymes, rational 
approaches can be tested to correct of the skin symptomatology in ichthyosis patients with 
several different gene mutations. For patients with inactivating mutations in ALOX12B or 
ALOXE3, the prediction is that they fail to oxidize EOS, thus it is not cleaved, and consequently 
there is a lack of OS available for construction of the CLE. Thus, topical application of OS is 
predicted to be palliative. The same treatment could be effective for mutations in the cytochrome 
P450 gene CYP4F22. CYP4F enzymes are fatty acid omega-hydroxylases and the CYP4F22 
mutations likely result in a deficit in omega-hydroxylated ceramides, although this remains to be 
shown. Again, topical application of OS (and for CYP4F22 mutations, also EOS) may by-pass 
the block in the pathway. In addition to the potential therapeutic benefits, the results should be 
informative on the roles of key players (ALOX12B, ALOXE3, CYP4F22, and ICHTHYIN) and the 
requirement for esterified or free hepoxilin-type products in barrier function. 
Conclusions 
We hypothesize that two epidermal lipoxygenases, 12R-LOX and eLOX3 act in tandem to 
oxidize the linoleic acid molecules of the ceramides EOS. Hepoxilins, as oxidation 
intermediates, would act as a signal which allows the recognition and hydrolysis of the linoleic 
acid and the conversion of ceramides EOS into ceramides OS. Thereafter, the ω-hydroxy fatty 
acid chain of the resulting ceramides OS covalently binds to proteins of the corneocytes to form 
the lipid envelope. This step is necessary to form a competent skin barrier. Understanding the 
role of hepoxilins in the epidermis can lead to a rational basis for therapy of diseases that disrupt 
the normal development of the barrier to water vapor diffusion of the skin, such as autosomal 
recessive congenital ichthyoses. 
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Figure Legends 
Figure 1. Structural components of the epidermal barrier  
This cartoon shows the arrangement in and around corneocytes in the barrier layer, with a close-
up illustrated in the segment below. In the stratum corneum, a coat of polymerized protein, the 
corneocyte envelope (CE) lies just inside the periphery of the flattened corneocytes. Bonded to 
the CE is a monolayer of covalently-bound ceramides and fatty acids, the corneocyte lipid 
envelope (CLE). The CLE is considered to act as a scaffold for organization of the lamellae of 
extracellular lipids comprised of cholesterol, ceramides, and fatty acids. This figure was 
originally published in The Journal of Biological Chemistry [87] © the American Society for 
Biochemistry and Molecular Biology. 
 
Figure 2. Expression of 12R-LOX mRNA in human epidermis 
Top: the bright-field view shows an H & E stained section of human abdominal skin. Below: the 
dark-field view shows hydridization of the antisense probe (radiolabeled cRNA specific for 
human 12R-LOX) over the outermost epidermal cells that retain a nucleus (upper stratum 
granulosum). Discarded human skin tissue was obtained according to protocols approved by 
Vanderbilt University Institutional Review Board. In situ was performed as described [98-100]. 
 
Figure 3. Lipoxygenase catalysis to hepoxilins and trioxilins 
In this example, linoleic acid (top) is metabolized by 12R-LOX to 9R-hydroperoxy-linoleic acid, 
a potential substrate for conversion to HxA-type of HxB-type hepoxilins by eLOX3. Hydrolysis 
of the epoxide gives trihydroxy fatty acids (Trioxilin-type triols). 
 
Figure 4. Epidermal specific ceramides 
EOS in the outer epidermis is esterified mainly with linoleic acid (C18:2) and is glucosylated at 
C-1 of the sphingosine (Glc-EOS) early in differentiation. After hydrolysis of the glycosidic and 
ester bonds, the resulting OS is esterified by transglutaminase (TGase) to glutamines in the 
cross-linked proteins of the CE [25]. The ester linkage in the resulting glutamates bonds the 
monomolecular lipid coating, the CLE, to the outer face of the CE. -Hydroxy-VLFA (OAcid, 
shown on the right side) are also ester-linked components of the CLE. This figure was originally 
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published in The Journal of Biological Chemistry [87] © the American Society for Biochemistry 
and Molecular Biology. 
 
Figure 5. Ceramides, essential fatty acids and lipoxygenases and their proposed role on 
maturation of the epidermal water barrier 
(1) Lamellar granules contain lamellar lipid discs with acylglucosylceramides (Glc-EOS, with 
linoleate coupled to the omega-hydroxyl) in the limiting membrane. (2) Fusion combines the 
lamellar limiting membrane with the cell plasma membrane, an early stage in formation of the 
corneocyte lipid envelope (CLE, shown greatly expanded) and extrudes the lamellar contents 
extracellularly. (Glucosyl)-EOS has the very long chain fatty acid component (long red line) 
spanning the lipid bilayer, with linoleate (black line with two (white) double bonds) folded into 
the bilayer. (3) Progression towards the mature barrier entails LOX-catalyzed oxygenation of the 
linoleate in the ceramide by the consecutive actions of 12R-LOX and eLOX3. (4) The resultant 
“oxygen signal” permits esterase-catalyzed hydrolysis of the oxidized linoleate, freeing the 
ceramide omega-hydroxyl. (5) Transglutaminase-catalyzed covalent coupling of the CLE to the 
cross-linked proteins of the CE, thus helping to seal the barrier. A part of this figure was 
originally published in The Journal of Biological Chemistry [87] © the American Society for 
Biochemistry and Molecular Biology. 
 
Figure 6. Proposed pathway of the LOX products in the skin and its relationship with the 
formation of the permeability barrier. LOX = Lipoxygenases; FATP4 = Fatty acid transport 
protein 4; PPAR = Peroxisome proliferator activated receptor; RXR = Retinoid X receptor, a 
molecule with which PPAR forms a heterodimer, which binds to the DNA of the target gene; 
EFA = Essential fatty acid; Cer-EOS = Ceramide EOS; Cer-OS = Ceramide OS; Hx = Hepoxilin; 
HX-EOS = Hepoxilin-EOS.  
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